Former director of FDA joined Illumina's board of directors, Kang Zhe, to fight short
-
Last Update: 2020-02-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
(2020 / 02 / 10) important signaling pathways in lymph nodes were revealed to better understand the pathophysiological process; sher0302, a new class 1 drug of Hengrui, was approved for clinical use in alopecia areata; Scott Gottlieb, former director of FDA, joined the board of directors of Illumina; jienovartis 2019 financial report: China's market revenue increased by 2.2 billion US dollars in double digits Since leaving the FDA, Scott Gottlieb has been employed as a director by several pharmaceutical companies At present, shr0302 has been approved for 8 clinical trials Insomnia is a sleep disorder that makes it difficult for the patient to fall asleep and / or stay asleep China, a key market for Novartis, contributed $2.2 billion (double-digit growth) Malicious digging, but a new Kang zhe pushed out.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
